Fare Capital

MyLife Technologies B.V., founded in 2012 and based in Leiden, the Netherlands, specializes in the development and commercialization of nanoporous MicroNeedle Arrays (npMNAs) integrated into skin patches for drug delivery. The company is focused on creating innovative solutions for vaccine administration, particularly through its ceramic microneedle technology, which enables intradermal delivery of vaccines and drugs. This technology offers a more efficient alternative to traditional muscle injections, eliminating the need for cold chain logistics and providing a completely pain-free experience for patients. MyLife Technologies aims to respond swiftly to infectious disease outbreaks by collaborating with partners to develop intelligent skin patches that enhance patient treatment options.